MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Catalyst Pharmaceutical Partners Company Profile (NASDAQ:CPRX)

Consensus Ratings for Catalyst Pharmaceutical Partners (NASDAQ:CPRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.42 (355.56% upside)

Analysts' Ratings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Piper JaffrayDowngradeOverweight -> Neutral$6.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2016SunTrustReiterated RatingBuy$7.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2014AegisBoost Price TargetPositive$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.09)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.05)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2014Q114($0.06)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/15/2012Q312($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.06)($0.06)($0.06)
Q2 20161($0.06)($0.06)($0.06)
Q3 20162($0.06)($0.06)($0.06)
Q4 20162($0.07)($0.06)($0.07)
(Data provided by Zacks Investment Research)
Dividend History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateHeadline
06/29/16 10:40 AMShare Update and Earnings Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph
06/28/16 08:16 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:02 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an -
06/23/16 02:44 PMCan Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Surprise Analysts this Quarter? - Investor Newswire
06/22/16 03:32 PMCatalyst Pharmaceutical Partners, Inc. (CPRX) Current Analyst Ratings - Fiscal Standard
06/10/16 04:02 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule -
06/10/16 04:02 PMCatalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/07/16 03:49 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters t -
06/05/16 08:41 PMAfter Last Week What Do Analysts Think Of Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News
06/04/16 08:43 PMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update & Estimates - Stock Tick Tock
06/02/16 09:22 PMStrong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0 - Investor Newswire - Strong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0Investor NewswireCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has a total of 3 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2 ...and more »
06/01/16 11:34 AMStock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - HNN - Stock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Catalyst Pharmaceutical Partners, ...and more »
05/30/16 12:34 PMCatalyst Pharmaceutical Partners, Inc. (CPRX) Broker Price Targets For The Coming Week - Share Trading News - Catalyst Pharmaceutical Partners, Inc. (CPRX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Catalyst Pharmaceutical Partners, Inc. (CPRX). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/25/16 11:21 AMEarnings Review and Stock Rundown for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Catalyst Pharmaceutical Partners, Inc.and more »
05/23/16 01:27 PMStock Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Stock Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.and more »
05/18/16 12:00 PMShare Recap and Earnings Focus on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsPresently, covering analysts are anticipating Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) to report quarterly EPS of $-0.07. The company's next earnings report is expected to be released on or around 2016-08-08 for the period ending on ...and more »
05/18/16 08:52 AMCatalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve - [at noodls] - May 18, 2016 CORAL GABLES, Fla., May 18, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/18/16 08:22 AMCatalyst (CPRX) Resorts to Layoffs for Firdapse Development -
05/18/16 07:03 AMCatalyst Pharmaceutical’s Firdapse Phase 3 Study Published in Muscle & Nerve - [GlobeNewswire] - CORAL GABLES, Fla., May 18, 2016-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, ...
05/17/16 04:20 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial -
05/17/16 07:42 AMCatalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan - [at noodls] - May 17, 2016 CORAL GABLES, Fla., May 17, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/16/16 01:49 PMConsensus Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Consensus Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate ...and more »
05/15/16 05:38 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) One-Year Mean Price Target At $5.25 - Stocks Daily - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) One-Year Mean Price Target At $5.25Stocks DailySell-side analysts are confident on the future outlook of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock. As of 2016-05-13, the stock has an ABR of 1.5 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the ...and more »
05/11/16 02:29 PMCatalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus -
05/10/16 05:35 PMCatalyst reports 1Q loss -
05/10/16 04:47 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/10/16 04:08 PMCatalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - May 10, 2016 CORAL GABLES, Fla., May 10, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative ...
05/10/16 03:51 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/10/16 06:07 AMQ1 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close -
05/10/16 05:36 AMCheck on Analyst Ratings Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Check on Analyst Ratings Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on ...and more »
05/10/16 05:36 AMPerformance Recap and Target Perspective on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialIn the latest trading session, shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) moved +4.519%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a ...and more »
05/08/16 05:20 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ABR Of 1.5 - Stocks Daily - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ABR Of 1.5Stocks DailyThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
05/06/16 07:14 AMCatalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016 - [at noodls] - May 6, 2016 CORAL GABLES, Fla., May 06, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/03/16 05:23 AMAverage Analyst Rating for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Average Analyst Rating for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.5 on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 05:23 AMThis Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News - The Point ReviewThis Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX)Share Trading News04/26/2016 – Catalyst Pharmaceutical Partners, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 1 price target on the stock. 02/18/2016 – Catalyst Pharmaceutical Partners, Inc. had its “buy” rating reiterated by ...Catalyst Pharmaceuticals Inc's Stock Formed A Several Months Bearish Wedge Down Chart PatternFranklin Independentall 3 news articles »
04/28/16 05:37 AMLatest Analyst Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News - Latest Analyst Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX)Share Trading News04/26/2016 – Catalyst Pharmaceutical Partners, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 1 price target on the stock. 02/18/2016 – Catalyst Pharmaceutical Partners, Inc. had its “buy” rating reiterated by ...
04/26/16 09:37 PMShare Performance and Target Price Review Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Share Performance and Target Price Review Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ended up with a move of -49.19%. Sell-side analysts have given a consensus target price of $7.06 on company shares. Target price projections may ...and more »
04/26/16 09:37 PMAnalyst Coverage: Catalyst Pharmaceutical Partners, Inc. (CPRX) - Risers & Fallers - Analyst Coverage: Catalyst Pharmaceutical Partners, Inc. (CPRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Catalyst Pharmaceutical Partners, Inc. (CPRX). The latest broker reports which are currently outstanding on Tuesday 26th of April state 0 analysts have a rating of “strong ...Catalyst Pharmaceuticals, Inc. (CPRX) Files Form 4 Insider Buying : Patrick J Mcenany Buys 50000 SharesMarket DigestPatrick Mcenany an Insider in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Acquired 50000 Shares of the CompanyFranklin IndependentPiper Jaffray Downgrades Catalyst Pharma to Neutral vs Overweight, Cuts PT to $1 vs $6 (NASDAQ:CPRX)Sonoran Weekly ReviewGlobeNewswire (press release)all 17 news articles »
04/26/16 12:18 PMWhy Is Catyalyst Pharma (CPRX) Stock Crashing Today? -
04/26/16 07:33 AMCatalyst Pharma downgraded by Piper Jaffray -
04/26/16 06:16 AMCatalyst Pharmaceuticals Provides Regulatory Update on Firdapse - [at noodls] - April 26, 2016 CORAL GABLES, Fla., April 26, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
04/26/16 05:57 AM6:57 am Catalyst Pharma provides regulatory update on Firdapse, FDA states additional 'positive' results from a well-controlled study in patients with LEMS will need to be submitted, notes cash balance of ~$52 mln as of Mar 31 -
04/22/16 06:04 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Analyst Rating Review - B.O.D.Y Confidential - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Analyst Rating ReviewB.O.D.Y ConfidentialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 5 analysts that have provided ratings for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). 4 have rated ...and more »
04/21/16 06:00 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Book Value Stands At $0.73 - Investor Newswire - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Book Value Stands At $0.73Investor Newswireb>Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has a 52-week price target of $7.06. This price estimate by Thomson Reuters shows the average of the stock recommendations collected by First Call. The EPS of the company in the last year ...and more »
04/20/16 06:32 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Is Trading $-0.93 Away Its 200-day MA Of $2.13 - Investor Newswire - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Is Trading $-0.93 Away Its 200-day MA Of $2.13Investor NewswireThe technical analysis of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock confirms it is trading $0.03 away +2.79% from its fifty-day moving average of $1.17, and it is trading $-0.93 or -43.58% away 200-day MA of $2.13. After the last close ...
04/19/16 06:15 AMCheck on Stock Rating Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Business Standard Tribune - Check on Stock Rating Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Business Standard TribuneCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) currently has a rating of 1 on shares. On a scale from 1 to 5, a rating of 1 or 2 would represent a Buy. On the same scale, a stock rating of 4 or 5 would represent a Sell. A rating of 3 would ...and more »
04/15/16 09:20 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX): Quick Look at Earnings - News Tribune - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX): Quick Look at EarningsNews TribuneWhen Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) issues their next quarterly report on or near 2016-05-09, Wall Street analysts are predicting they will report earnings per share of $-0.07. This consensus EPS number is provided by Zacks ...
04/15/16 09:20 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Analyst Recommendation Outlook - Clinton Financial - Clinton FinancialCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Analyst Recommendation OutlookClinton FinancialThere are 5 analysts providing ratings for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). 4 have given the stock a “Strong Buy”, 0 rate it a “Buy”, 0 are rating the stock a Hold, and 0 are recommending “Sell”. Every recommendation can be mapped ...and more »
04/14/16 10:36 AMEarnings Watch on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - RiversideGazette.com - Earnings Watch on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)RiversideGazette.comCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has a consensus earnings per share estimate for the current quarter of $-0.07 based on compiled analyst projections. The company is next expected to release earnings on or around 2016-05-09 for the ...and more »
04/13/16 11:27 AMUpgrades And Downgrades For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Risers & Fallers - Upgrades And Downgrades For Catalyst Pharmaceutical Partners, Inc. (CPRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Catalyst Pharmaceutical Partners, Inc. (CPRX). The latest broker reports which are currently outstanding on Tuesday 12th of April state 0 analysts have a rating of “strong ...
About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.75
  • 50 Day Moving Average: $0.67
  • 200 Day Moving Average: $1.30
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $62.15M
  • Current Quarter EPS Consensus Estimate: $-0.30 EPS
Additional Links:
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha